The threat comes as Trump's administration pressures pharmaceutical companies to lower drug prices for Americans.

Driven by lessons from the pandemic and a reliance on imports -- more than $2.16 billion in packaged medicines in 2023, most ...

Elara Capital observes that Aurobindo Pharma has 14 biosimilars in the pipeline. The company has also filed 3 biosimilars for ...

President Donald Trump said on Tuesday that the United States would initially place a "small tariff" on pharmaceutical ...

Jerry Keybl, senior vice-president, Biopharma Products and Strategy, Avantor, discusses innovations in biomanufacturing and ...

The regulatory environment is placing extreme pricing pressure on pharmaceutical manufacturers. Their success in the market ...

President Trump plans tariffs of up to 250% on imported drugs to boost U.S. pharmaceutical manufacturing. While aimed at reshoring production, the proposal sparks industry concerns over rising costs ...

President Donald Trump plans to start with a “small tariff” on pharmaceutical imports before ramping duties up to 250% within ...

The US initiated a Section 232 investigation on pharmaceutical products in April, purportedly to verify the impact of imports ...

RFK Jr. announced that the U.S. government’s emergency preparedness agency will no longer fund work on mRNA vaccines ...

Learn more about whether Amneal Pharmaceuticals, Inc. or Ocular Therapeutix, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co ...